<DOC>
	<DOC>NCT00148707</DOC>
	<brief_summary>The purpose of this study is to collect information on what effects (good or bad) CT-2103 (Xyotax) has on breast cancer as well as any side effects the drug may cause.</brief_summary>
	<brief_title>Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>- Patients will be given CT-2103 intravenously every 3 weeks. One week after the first dose of CT-2103 a physical exam, blood work and assessment of any side effects will be performed. - Prior to each injection of CT-2103, a physical exam, blood work and assessment of any side effects will be performed (every 3 weeks). - Every 6 weeks the patient's cancer will be re-evaluated with either a CT scan or MRI to determine whether the treatment is working. - Additional blood work will be performed once per week after the first two doses of CT-2103. - The participation in this study will last at least 2 cycles (6 weeks), however patients may remain on the study as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of invasive breast cancer, Stage IV disease Age greater than 18 years At least one measurable target lesion as defined by RECIST that has not been previously treated with local therapy HER2negative breast cancer Up to one prior chemotherapy for advanced or metastatic disease ECOG performance status 01 Life expectancy &gt; 12 weeks Adequate liver and bone marrow function: AST &lt; 2.5 x ULN; Bilirubin &lt; 1.5 x ULN; ANC &gt; 1,500/ul; platelet count &gt; 100,000/ul; normal PT and PTT At least 2 weeks since prior radiation and recovered from treatmentrelated toxicity Prior taxanes for treatment of metastatic disease Pregnant of breastfeeding women HER2positive breast cancer More than 1 prior chemotherapy regimen for metastatic disease Untreated brain metastases Concurrent radiotherapy or investigational drug Prior bone marrow or stem cell transplant History of other malignancy within the last 5 years, not including curativelytreated carcinoma in situ of the cervix or nonmelanoma skin cancer Uncontrolled infection Active bleeding, or history of bleeding requiring transfusion Active cardiac disease Serious medical or psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2-negative Breast Cancer</keyword>
	<keyword>CT-2103</keyword>
	<keyword>Xyotax</keyword>
</DOC>